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Abstract. Rheopheresis is an extracorporal selective double-filtration procedure. In the first part of the treatment the blood8
is passes through the plasma filter, which separates blood cells from the plasma. Then the plasma flow to a second filter9
called MONET (Membranefiltration Optimised Novel Extracorporal Treatment). The MONET filter retains high molecular10
weight proteins such LDL, Lp(a), fibrinogen, 2 macroglobulin, vWF and IgM. Hereby the whole blood and plasma viscosity11
decrease, improves microcirculation, and has a positive effect on lipid profile as well.12
Accorging to ASFA recommendation rheopheresis is a first line treatment in age-related dry macular degeneration and in13
sudden sensorineural hearing loss. There are other clinical situations in which rheopheresis has been used effectivly. But only14
few data are available and large clinical trials have not been done in these diseases. In this paper we describe a case history15
and laboratory findings of a patient who suffers from age related dry macular degeneration and was successfully treated by16
rheopheresis.
17
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1. Introduction19
During the past few years several novel therapeutic apheresis methods were introduced, significantly20
widening the indication range of apheresis therapies. One of these new therapeutic procedures is called21
rheopheresis, which is classified into the group of selective extracorporal haemotherapies. Rheopheresis22
is a 2-step cascade filtration procedure [20]. As the first step of the treatment cellular elements are sep-23
arated from the plasma, then the plasma flows through a special filter which is able to eliminate certain24
plasma components based on molecular size, or at least it is able to reduce their level significantly [3].25
With the help of the MONET filter (Membrane filtration Optimised Novel Extracorporal Treatment)26
developed by Fresenius SE (Bad Homburg, Germany) the opportunity to perform a rheopheresis is27
provided. With this method proteins with molecular weights higher than 250–300 kDa can be eliminated28
from the plasma. After that the purified plasma is administered to the patient through a peripheral vein,29
together with the cellular elements. LDL, Lp(a), fibrinogen, 2 macroglobulin, vWF and IgM are30
some of those proteins of high molecular weight which are eliminated this way. Averagely, 1 treatment31
reduces the LDL level by approximately 70%, the total cholesterol level by 50%, and it decreases32
the triglyceride level generally by 35–40%. The fibrinogen level is also reduced to its half in general,33
after one treatment. On the other hand it needs to be highlighted that HDL level does not change34
significantly, neither do plasma albumin nor total protein levels [19].35
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Besides the above mentioned facts they also observed that rheopheresis is able to decrease Lp(a),36
vWF and IgM levels as well. The favourable effect of the rheopheresis therapy is resulting from the37
beneficial changes in levels of these macromolecules. As a result of this, treatment viscosity of the38
plasma and the whole blood is reduced, the erythrocyte aggregation is moderated and deformability39
of the erythrocytes is improved [3, 22].40
As a consequence of these, blood flow is improved, and dysfunctions of the microcirculation are41
also alleviated. It has a beneficial effect on lipid profile as well, it decreases the level of atherogenic42
lipid fractions in blood, but at the same time it does not significantly alter the levels of protective HDL.43
Indication range of rheopheresis has been widened during the past few years. They conducted trials44
with rheopheresis in different disease groups, however, randomized, prospective clinical trials were45
only conducted in case of age-related macular degeneration and sensorineural hearing loss [4, 17].46
Rheopheresis was applied in case of patients with peripheral arterial vascular diseases, who were not47
suitable for revascularization or who suffered from diabetic leg syndrome [9]. Futhermore beneficial48
effects were detected on the blood flow in the carotid artery and on the vasodilatory capacity of the49
coronary arteries [6].50
Based on double blind, placebo-controlled trials, and 2013 guidelines of the American Society for51
Apheresis (ASFA), rheopheresis is the recommended first choice of therapy in case of dry form of52
age-related macular degeneration.53
Age-related macular degeneration (AMD) is a special angiological disease, which has two different54
types, dry and exudative form. About 80% of all AMD cases are dry forms. It shows the significance55
of AMD that based on a WHO survey it is responsible for 50% of ophthalmological diseases lead-56
ing to blindness in Western countries, and the ratio is similar in Hungary [15]. The disease shows57
direct correlation with cholesterol, fibrinogen and alpha-macroglobulin levels. Its pathomechanism is58
multi-factorial, in which several different mechanisms pay role, such as inflammatory involvement of59
chorio-capillaries, lipid accumulation, haemorheological disorders and dysfunctions of microcircula-60
tion. Among the subjective symptoms we have to outline that the patient initially sees a blurred area,61
which is always in the way of sight (central visual impairment). Currently there are no available causal62
treatments, but progression can be slowed down with conservative therapy and moderation of the risk63
factors. In case of dry form of AMD we can administer antioxidant vitamins, zinc, lutein, or zeaxantin64
containing dietary supplements, as well as nutrients rich in unsaturated fatty acids, and in case of the65
exudative form of AMD, intra-vitreal pharmacotherapy (VEGF inhibitors) is recommended [1–2, 14].66
2. Case report67
In the medical anamnesis of our 68-year-old male patient, medical care due to hypertension and68
asthma, as well as TIA is listed. Considering his risk factors, he has been a heavy smoker for 30 years,69
but he quit smoking in 2009. No ophthalmological diseases are present in familial medical anamnesis.70
His eye-related complaints started to emerge during summer of 2013 he experienced blurred vision71
and central visual field loss. Based on the dilated fundus examination, optical coherence tomography72
(OCT), and fluorescent angiography we diagnosed dry type age-related macular degeneration in the73
background of his complaints. In line with the most intensive conservative therapy (zinc and lutein74
containing dietary supplements) his visual loss progressed continuously. By the spring of 2014, his75
visual impairment made him unable to read. Because of the rapidly progressing condition–despite the76
conservative therapy – we decided to perform a rheopheresis treatment together with the Department of77
Ophthalmology. Before we initiated the therapy we obtained a licence from the local Ethics Committee78
and the written informed consent form signed by the patient.79
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The first rheopheresis treatment was performed in July 2014 at the ICU of our clinic. Between July80
2014 and July 2016 the patient received 6 cycles of rheopheresis treatment, altogether for 11 times.81
The rheopheresis treatment was performed with the use of a MONET filter. No complications or side82
effects were observed during the course of the therapy.83
For efficacy assessment of the rheopheresis treatment we performed laboratory tests and angiological84
examinations–besides the ophthalmological tests–preceding the treatment cycles, as well as at the85
end of each therapeutic cycle. According to our assumption, rheopheresis treatment not only works86
via improvement of viscosity to moderate microcirculatory dysfunction, but it may have other anti-87
inflammatory effects, and it might decrease the level of endothelial and thrombocyte activating markers.88
All these beneficial effects may result in improving the endothelial functions.89
3. Rheopheresis90
The rheopheresis treatment was performed by using the MONET (Membrane filtration Optimised91
Novel Extracorporal Treatment) filter developed by Fresenius Medical Care Deutschland GmbH. The92
MONET filters were attached to Art Universal devices. For the extra-corporal treatment, cannula-93
tion of two peripheral veins is necessary. As first step of the therapy we separate the plasma from94
the cellular components of blood with the help of a plasma filter, then the plasma is made to flow95
through the MONET filter. After that the purified plasma is administered into the patient’s circulatory96
system through a peripheral vein, together with the cellular elements. Citrate was administered as an97
anticoagulant.98
4. Haemorheological measurements99
Determination of the viscosity of the whole blood and plasma (WBV, PV [mPa.s]) was performed100
with a Hevimet-40 capillary viscometer (Hemorex Ltd., Hungary). Viscosity values at 90 s−1shear rate101
were used for comparison. According to the Ma´trai-formula, the whole blood viscosity data were also102
corrected to 40% hematocrit value [8, 12]. Deformability of erythrocytes was measured by a rotational103
ektacytometer (LoRRca MaxSis Osmoscan, Mechatronics BV, The Netherlands). Elongation index (EI)104
was plotted in the function of shear stress (SS [Pa]). RBC aggregation was determined concomitantly105
with two different methods. First we used a Myrenne MA-1 erythrocyte aggregometer (Myrenne106
GmbH, Germany), the operation of which is based on light transmission. Aggregation indices were107
determined under stasis (M mode) and at 3 s−1 sh ar rate (M1 mode), at the 5th and the 10th second of108
the aggregation (M 5 s, M 10 s, M1 5 s, M1 10 s). The LoRRca system characterizes the aggregation109
process based on light reflection (syllectometry). For comparison the following parameters were used:110
aggregation index % (AI), amplitude (Amp), t1/2 [s].111
4.1. Laboratory tests112
Phagocyte activity was measured by chemiluminescence method. Heparinized human whole blood113
was used. Samples were diluted by PBS (phosphate buffered saline), in the ratio of 1 : 3. In the control114
tubes, 0.5 ml of diluted blood was diluted to 1 ml by adding 0.5 ml of PBS. For the stimulation of115
phagocytes, 0.5 ml of zymosan suspension (1 mg/ml zymosan, Sigma, MO, USA) was added. As116
positive control, phagocytes were stimulated by 0.5 ml PMA (0.04g/ml, phorbol-myristate-acetate,117
Sigma). The amplification of free radical production (chemi-luminescence, CL) took place by the118
addition of 50l luminol (20g/ml, 5 amino-2,3 dihydro-1,4 phtalazinedione, Sigma). The CL was119
measured by an AutoLumat LB 953 multi-tube luminometer (Berthold Technologies, Germany). Both120
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the non-stimulated controls (basal CL), the zymosan-stimulated and the PMA-stimulated whole blood121
samples were tested in duplicate. Their CL was detected in every 3 minutes for 45 minutes. Results122
are presented as the area under the relative-light unit (RLU) curves and the maximum values of123
RLUs.124
Activated monocytes (CD14+CD16+) were measured by flow cytometry from heparinized whole125
blood. Cells in 100l blood were stained with 10-10l of monoclonal antibodies (anti-CD16-FITC,126
anti-CD14-PE, Becton Dickinson, USA). Mouse IgG1-FITC, IgG1-PE (Becton Dickinson, USA) was127
used as an isotype control. After 25 min incubation the red blood cells were haemolysed and the128
leukocytes were washed with PBS (completed with BSA and sodium-azide). Finally the cells were129
suspended in 800l of 1% para-formaldehyde. Samples were measured by a Beckman Coulter FC500130
flow cytometer and analysis was carried out by CXP software (Beckman Coulter, USA). Monocytes131
were gated on the basis of their side-scatter parameter and CD14 positivity. Results were expressed as132
the percentage of CD16+ cells in the gated CD14+ monocyte region.133
Determination of lipid proﬁle (cholesterol, triglyceride, LDL, HDL, Lp(a) levels) was performed134
based on routine laboratory diagnostic tests at DE KK LMI (University of Debrecen, Clinical Centre,135
Institute of Laboratory Medicine). Analyses were performed from 4 ml blood samples, free from136
anticoagulants. Determination of fibrinogen was done from blood sample t eated with Na-citrate137
anticoagulant, according to the Clauss method. The reference range was: 1.5–4 g/L.138
Measurement of vWF:Ag level was performed from blood sample treated with Na-citrate anticoag-139
ulant. The whole blood was first centrifuged (1500 g, 20 min, 22◦C), then from the plasma obtained140
this way, level of vWF:Ag was determined by immuno-turbidimetry. The degree of agglutination is141
directly proportional to the level of vWF found in the sample. The reference range was between 50142
and 160%.143
P-selectin expression characterising thrombocyte activation was determined from whole blood144
treated with citrate anticoagulant, with the help of anti-CD-62 monoclonal antibodies. Measurements145
were done by flow cytometer. Reference range of thrombocyte P-selectin was: 0–2%.146
Flow-mediated vasodilatation (FMD) was performed by ultrasound technic. Examinations were147
performed under standardized conditions on the patient, after 8 hours of fasting and 18 hours of smok-148
ing prohibition, on the right brachial artery. Measurements were made with Phillips (HD11XE) high149
resolution ultrasound device, with a 5–10 MHz linear transducer. ECG monitoring was performed150
during the whole examination. We took longitudinal cross-sectional images of the brachial artery151
proximally from the elbow, and we determined the diameter of the artery between at least 5 identi-152
cal points. Measurements were made synchronized to the R-wave. After that we triggered reactive153
hyperaemia, first by bloating the sphygmomanometer cuff placed onto the forearm for 4.5 minutes,154
maintaining a supra-systolic value 50 mmHg above the systolic pressure, then suddenly deflating the155
cuff. We detected the change in the aortic diameter within the 60th second following the cuff defla-156
tion, accordingly to the method detailed above. The flow-mediated dilation was given as a percentage157
value, which expresses the diameter change triggered by reactive hyperaemia, compared to the resting158
diameter.159
Arterial stiffness determination (augmentation index, pulse wave velocity) was done with the help of160
a Tensio Clinic arteriograph (TensioMed Kft., Debrecen). The measurement is based on the principle161
that as a result of contraction of the heart, the first pulse wave generated in the aorta is reflected at the162
level of bifurcation, thus an easily detectable second wave (late systolic peak) appears during systole.163
Morphology of the second wave depends on stiffness parameter of the common carotid artery, on164
the reflection time measured on the brachial artery at 35 mmHg supra-systolic pressure (RT S35), as165
well as on peripheral resistance defined by the amplitude of the wave. The pulse wave velocity is166
the distance between the jugular fossa and the symphisis, and ratio of the RT S 35 value. Unit of the167
quotient obtained this way is m/s.168
Un
co
rre
cte
d A
uth
or
 P
ro
of
M. Vass et al. / Rheopheresis in vascular diseases 5
Ophthalmological examination determined the best corrected visual acuity of the patient on a loga-169
rithmic scale, we took colour photos of the eye fundus (TRC-NW7SF, Topcon, Tokyo, Japan) and we170
performed an OCT (Zeiss Stratus, Carl Zeiss Meditec, Inc, California USA) examination.171
5. Results172
5.1. Ophthalmological results173
Even the first cycle of therapy resulted in significant improvement in visual acuity. Reading ability174
of the patient was restored, he was able to read with a magnifier.175
The objective best corrected visual acuity showed fluctuation, but no progression could be detected.176
Based on the examination of the eye fundus, the wasting of the right eye was not aggravated as a result177
of the therapy, and sub-retinal bleeding of the left eye absorbed completely by the end of the third178
cycle of therapy (Fig. 1). The OCT examination performed prior to the treatments showed extended179
retinal pigment epithelium (RPE) atrophy on the right side, pigment aggregation, thinned neuroretina180
and presence of sub-retinal fibro-vascular membrane in the left eye. In addition, pigment epithelial181
abruption distorting the fovea, and nasally from the centre, a small amount of sub-retinal fluid could182
be detected. By the end of the therapeutic cycles the contour of the fovea on the right became even,183
no progression was observed, neither intra-retinal nor sub-retinal fluid was visible on the left eye, and184
the pigment epithelium abruption also ceased (Fig. 2).185
5.2. Changes of haemorheological and lipid parameters as a result of rheopheresis186
Viscosity of whole blood and the plasma was increased prior to the first treatment, and increased187
erythrocyte aggregation was also measured, in line with borderline fibrinogen level. It can be observed188
that by the end of the first therapeutic cycle viscosity of the plasma returned to the normal range, viscos-189
ity of the whole blood also decreased significantly, it almost reached the reference range. Erythrocyte190
aggregation normalized and fibrinogen level also decreased. During the additional therapeutic cycles191
we observed obtained similar results (Table 1). In case of our patient lipid parameters were already192
within the normal range before initiation of the rheopheresis, due to the long-term statin therapy that193
he received because of secondary prevention of the formerly developing TIA. But still, our results194
prove that rheopheresis therapy was able to effectively decrease the level of atherogenic lipid fractions195
during the treatment cycles.196
5.3. Anti-inﬂammatory, thrombocyte and endothelial activation moderation effects197
of rheopheresis198
Prior to the first therapeutic cycle significantly increased phagocyte activity and increased199
CD14+/CD16+ cell population ratio were detected. Our results support the hypothetic inflammatory200
involvement of chorio-capillaries in pathogenesis of AMD. After the first treatment session, as a result201
of that phagocyte activity and CD14+/CD16+ cell population ratio normalized. Based on all these we202
assume that rheopheresis therapy has – besides the decrease in known macromolecular levels – other203
effects as well, for the detection of which further tests should be performed.204
Rheopheresis treatment also moderated thrombocyte aggregation, which was evidenced by decrease205
and normalization of P-selectin expression.206
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Table 1
Changes of laboratory parameters after rheopheresis treatments
Treatment period 1 Treatment period 2 Treatment period 3 Treatment period 4 Treatment period 5 Tretament period 6
Before After Before After Before After Before After Before After Before After
Whole Blood-Plasma 6.28 4.34 4.25 4.22 5.1 4.8 5 4.19 4.44 4.1 4.57 4
viscosity (mPa sec)
1.55 1.17 1.25 1.19 1.38 1.18 1.47 1.3 1.45 1.35 1.67 1.67
Ert aggregability Increased Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal
Fibrinogen (g/l) 3.29 2.43 3.05 2.49 4.36 2.09 4.24 2.19 3.71 3.5 3.99 3.57
Tg (mmol/l) 0.8 0.6 0.5 0.4 0.7 0.9 0.7 0.7 0.7 0.6 0.8 0.7
Cholesterine (mmol/l) 3.6 2.1 4.6 2.8 4.2 1.8 4.5 2.3 3.3 1.6 4.3 2.4
LDL-C (mmol/l) 2.5 0.8 3 1.2 2.7 0.7 3 1.3 2.9 1.1 2.9 1.1
Lp(a) (mg/l) 141 69 135 69 60 32 80 58 62 42 62 42
CD14+/CD16+ activated 70.9 34.3 14.6 13.2 13.5 11.1 8.8 8.2 12 10 13 10
monocyte ratio (%)
Fagocyte activity 12938 3452 525 422 2852 1895 122 115 43.8 108 104.9 111.8
(RLU/30 min)
P-selectin expression (%) 3.15 1.1 1.57 1.12 1.27 2.6 1.32 2.33 1.3 0.9 1.94 1.94
vWF:Ag (%) 114 90 107 89 116 86 121 81 124 110 131 80
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Fig. 1. Picture of the patient’s coloured fundus: before the 1st treatment (A), after the 2nd (B), and after the 3rd treatment (C).
5.4. Effect of rheopheresis on endothelial function and on stiffness parameters207
Beneficial effects emerging as a result of rheopheresis therapy may not only be exhibited via enhanc-208
ing blood flow and improvement of microcirculation. According to our assumption these effects can209
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Fig. 2. OCT image: before the 1st rheoferezis treatment (on the top), after the 2nd treatment (in the middle) and after the 3rd
treatment (below).
improve macrocirculation as well. Within the confines of this endothelial dysfunction may be improved,210
as well as stiffness parameters (Fig. 3a,b,c). Our results support the observation that resulting from the211
rheopheresis therapy endothelial dysfunction eased, and it also had a positive effect on vascular wall212
stiffness. Based on all these rheopheresis may have potential application in the treatment of vascular213
disease developing as a result of atherosclerosis.214
6. Discussion215
The age-related macular degeneration is a leading cause of severe visual impairment and blindness216
of the population above the age of 60 in developed countries. Vast majority, about 80% of all AMD217
cases are classified into the group of dry type.218
The risk of developing the disease increases exponentially with ageing.219
Smoking unambiguously affects the development and course of the disease, but alcohol consumption,220
obesity, pathological BMI can also be influencing factors.221
Dry type AMD does not have a causal therapy currently. The following new strategies are available222
regarding the treatment of dry type AMD: a.) decreasing the development of drusen, b.) alleviating223
the inflammation, c.) decreasing the retinal oxidative stress and accumulation of toxic metabolites, d.224
increasing the chorioidea perfusion e.) enhancing regeneration of RPE and photoreceptor cells, f. gene225
therapy [5].226
Besides the above mentioned, rheopheresis also became available, at the University of Debrecen,227
Hungary was the first where it was introduced.228
The few larger trials, such as the Trial-Art and RheoNet study reported positive rheological, angi-229
ological and ophthalmological effects, which we were also able to observe [10–11]. Wolf at al. have230
found correlation between retinal microcirculation, plasma viscosity and visual function in patients231
with macroglobulinemia [23]. Mechanism of action of the treatment at the level of the retina is232
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A B
C
Fig. 3. (a) The effect of rheoferesis treatment on augmentation index, (b) The effect of rheopheresis on pulse wave velocity,
(c) The effect of rheopheresis treatment on flow mediated vasodilatation.
probably exhibited via enhancing tight attachment of photoreceptor external/internal segments to the233
foveal area [18]. It can be especially efficient in such dry AMD forms, like in our case, where pigment234
epithelium detachment is present with sub-retinal fluid. The latter was completely absorbed by the end235
of the treatment, and the contour of the fovea was confirmed to be even by OCT. On contrary to this,236
the almost 10-year-old MIRA study was not able to provide the initially promising achievements on237
long term, but the selection criteria were not unified [16]. Recently, according to the guidelines of the238
American Society for Apheresis (ASFA), they recommend rheopheresis as a first choice of treatment239
in case of dry form of AMD, based on strong evidence specified in a comprehensive evidence-based240
meta-analysis [21].241
Ourexaminationssupported thehypothesis thatbesides theabovementionedeffectsof rheopheresis, it242
may have other vascular and angiological impacts. In line with normalization of viscosity parameters and243
decreasing the levelsofatherogenic lipid fractions, itwasproven that rheopheresishasanti-inflammatory244
effect as well, and it also moderates thrombocyte activation, which has additional beneficial effects too.245
In addition to all the above mentioned facts, we also found evidence that rheopheresis therapy may246
improve endothelial functions and stiffness parameters. These effects might have the outmost impor-247
tance regarding the treatment of vascular diseases developing as a result of atherosclerosis. However,248
further examinations are needed to discover vascular target points of rheopheresis in details.249
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